Major Players in Japan Psychosis Market | Competitive Landscape 2026

Japan Psychosis Market Overview

According to 6Wresearch, the Japan psychosis market is experiencing significant growth due to the rising prevalence of mental disorders, increasing geriatric population, and growing adoption of advanced antipsychotic therapies. The growth of psychiatric care facilities, government initiatives for mental health awareness, and increasing investments in healthcare are further expected to boost the market.

Competitive Landscape

The competitive landscape in Japan psychosis market is a mix of global pharmaceutical giants and established regional companies. These companies provide a variety of products ranging from oral to injectable antipsychotics, long-acting formulations, and digital mental health support systems.

Leading Players Operating in the Japan Psychosis Market:

1. Otsuka Pharmaceutical

A global pioneer in the CNS segment, Otsuka provides sophisticated psychiatric solutions—including Abilify and Rexulti—that handle complex treatment adherence and long-term symptom management.

2. Sumitomo Pharma

A historic innovator in psychiatry, Sumitomo leverages its deep R&D heritage to provide high-quality therapeutic alternatives, such as the atypical antipsychotic Lonasen, for clinics across Japan.

3. Mitsubishi Tanabe Pharma

Focuses on advanced movement disorder therapeutics—such as valbenazine—supporting patients who require integrated care for antipsychotic-induced side effects.

4. Eisai Co., Ltd.

A leader in neuroscience, Eisai provides innovative pharmacological and diagnostic tools, focusing on the intersection of cognitive health and psychiatric wellness.

5. Meiji Seika Pharma

A major force in the domestic space, Meiji focuses on patient-centric formulations like orally disintegrating tablets that ensure treatment adherence for high-need patients.

6. Viatris Inc.

Combines global scale with local automation, offering a wide portfolio of psychiatric dosages in blister packs optimized for large-scale Japanese hospital distribution.

7. Sawai Pharmaceutical

A leading generic platform in Japan that leverages high-precision manufacturing to provide affordable, high-quality psychiatric tablets for diverse patient populations.

8. Nichi-Iko Pharmaceutical

Part of the core generic ecosystem in Japan, this brand focuses on providing highly customizable psychiatric tools integrated with broad hospital procurement applications.

9. Towa Pharmaceutical

Leverages decades of experience to provide technology-enabled system processing for psychiatric medications, specializing in tablet disintegration technology for better patient uptake.

10. EA Pharma

A specialty leader currently advancing trials for next-generation psychiatric treatments that target glutamatergic pathways for treatment-resistant populations.